ADVERSE REACTIONS SECTION.

6 ADVERSE REACTIONS. The most common adverse reactions for the single agent (>=20%) are nausea/vomiting, anemia, increased aspartate aminotransferase (AST), increased alanine aminotransferase (ALT), neutropenia, increased alkaline phosphatase, proteinuria, fever, hematuria, rash, thrombocytopenia, dyspnea, and edema. 6.1) To report SUSPECTED ADVERSE REACTIONS, contact Accord Healthcare Inc. at 1-866-941-7875 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . The following clinically significant adverse reactions are described elsewhere in the labeling: Hypersensitivity [see Contraindications (4)] Schedule-Dependent Toxicity [see Warnings and Precautions (5.1)] Myelosuppression [see Warnings and Precautions (5.2)] Pulmonary Toxicity and Respiratory Failure [see Warnings and Precautions (5.3)] Hemolytic Uremic Syndrome [see Warnings and Precautions (5.4)] Hepatic Toxicity [see Warnings and Precautions (5.5)] Exacerbation of Radiation Therapy Toxicity [see Warnings and Precautions (5.7)] Capillary Leak Syndrome [see Warnings and Precautions (5.8)] Posterior Reversible Encephalopathy Syndrome [see Warnings and Precautions (5.9)] Hypersensitivity [see Contraindications (4)] Schedule-Dependent Toxicity [see Warnings and Precautions (5.1)] Myelosuppression [see Warnings and Precautions (5.2)] Pulmonary Toxicity and Respiratory Failure [see Warnings and Precautions (5.3)] Hemolytic Uremic Syndrome [see Warnings and Precautions (5.4)] Hepatic Toxicity [see Warnings and Precautions (5.5)] Exacerbation of Radiation Therapy Toxicity [see Warnings and Precautions (5.7)] Capillary Leak Syndrome [see Warnings and Precautions (5.8)] Posterior Reversible Encephalopathy Syndrome [see Warnings and Precautions (5.9)] 6.1 Clinical Trials Experience. Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Single Agent:The data described below reflect exposure to gemcitabine as single agent administered at doses between 800 mg/m to 1250 mg/m intravenously over 30 minutes once weekly in 979 patients with various malignancies. The most common (>=20%) adverse reactions of single agent gemcitabine are nausea/vomiting, anemia, increased alanine aminotransferase (ALT), increased aspartate aminotransferase (AST), neutropenia, increased alkaline phosphatase, proteinuria, fever, hematuria, rash, thrombocytopenia, dyspnea, and edema. The most common (>=5%) Grade or adverse reactions were neutropenia, nausea/vomiting, increased ALT, increased alkaline phosphatase, anemia, increased AST, and thrombocytopenia. Approximately 10% of the 979 patients discontinued gemcitabine due to adverse reactions. Adverse reactions resulting in discontinuation of gemcitabine in 2% of 979 patients were cardiovascular adverse reactions (myocardial infarction, cerebrovascular accident, arrhythmia, and hypertension) and adverse reactions resulting in discontinuation of gemcitabine in <1% of 979 patients were anemia, thrombocytopenia, hepatic dysfunction, renal dysfunction, nausea/vomiting, fever, rash, dyspnea, hemorrhage, infection, stomatitis, somnolence, flu-like syndrome, and edema. Tables and present the incidence of selected adverse reactions and laboratory abnormalities reported in patients with various malignancies receiving single agent gemcitabine across clinical trials. Additional clinically significant adverse reactions are provided following Table . Table 5: Selected Adverse Reactions Occurring in >=10% of Patients Receiving Single Agent Gemcitabine Adverse Reactions Gemcitabine All Grades (%)Grade (%)Grade (%)a Grade based on criteria from the World Health Organization (WHO). For approximately 60% of patients, non-laboratory adverse reactions were graded only if assessed to be possibly drug-related. N=699-974; all patients with laboratory or non-laboratory data. Nausea and Vomiting 69131 Fever 4120 Rash 30<10 Dyspnea 233<1 Diarrhea 1910 Hemorrhage 17<1<1 Infection 161<1 Alopecia 15<10 Stomatitis 11<10 Somnolence 11<1<1 Paresthesias 10<10Table 6: Selected Laboratory Abnormalities Occurring in Patients Receiving Single Agent Gemcitabine Laboratory Abnormality Gemcitabine All Grades (%)Grade (%)Grade (%)a Grade based on criteria from the WHO. Regardless of causality. N=699-974; all patients with laboratory or non-laboratory data. Hematologic Anemia 6871 Neutropenia 63196 Thrombocytopenia 2441Hepatic Increased ALT 6882 Increased AST6762 Increased Alkaline Phosphatase 5572 Hyperbilirubinemia132<1Renal Proteinuria 45<10 Hematuria 35<10 Increased BUN 1600 Increased Creatinine 8<10Additional adverse reactions include the following:Transfusion requirements: Red blood cell transfusions (19%); platelet transfusions (<1%)Edema: Edema (13%), peripheral edema (20%), generalized edema (<1%) Flu-like symptoms: Fever, asthenia, anorexia, headache, cough, chills, myalgia, asthenia insomnia, rhinitis, sweating and/or malaise (19%) Infection: Sepsis (<1%)Extravasation: Injection-site reactions (4%)Allergic: Bronchospasm (<2%); anaphylactoid reactions. Ovarian Cancer Tables and present the incidence of selected adverse reactions and laboratory abnormalities, occurring in >=10% of gemcitabine-treated patients and at higher incidence in the gemcitabine with carboplatin arm, reported in randomized trial (Study 1) of gemcitabine with carboplatin (n=175) compared to carboplatin alone (n=174) for the second-line treatment of ovarian cancer in women with disease that had relapsed more than months following first-line platinum-based chemotherapy [see Clinical Studies (14.1)] Additional clinically significant adverse reactions, occurring in 10% of patients, are provided following Table 8. The proportion of patients with dose adjustments for carboplatin (1.8% versus 3.8%), doses of carboplatin omitted (0.2% versus 0) and discontinuing treatment for adverse reactions (11% versus 10%), were similar between arms. Dose adjustment for gemcitabine occurred in 10% of patients and gemcitabine dose was omitted in 14% of patients in the gemcitabine/carboplatin arm. Table 7: Adverse Reactions Occurring in >10% of Patients Receiving Gemcitabine with Carboplatin and at Higher Incidence than in Patients Receiving Single Agent Carboplatin [Between Arm Difference of >=5% (All Grades) or >=2% (Grades 3-4)] in Study a Grade based on National Cancer Institute CTC Version 2.0. Regardless of causality. Adverse ReactionsbGemcitabine/Carboplatin (N=175) Carboplatin (N=174) All Grades (%) Grade (%) Grade (%) All Grades (%) Grade (%) Grade (%) Nausea69606130 Alopecia49001700 Vomiting4660362<1 Constipation42613730 Fatigue403<13250 Diarrhea253014<10 Stomatitis/Pharyngitis22<101300Table 8: Laboratory Abnormalities Occurring in Patients Receiving Gemcitabine with Carboplatin and at Higher Incidence than in Patients Receiving Single Agent Carboplatin [Between Arm Difference of >=5% (All Grades) or >=2% (Grades 3-4)] in Study a Grade based on National Cancer Institute CTC Version 2.0. Regardless of causality. Percent of patients receiving transfusions. Transfusions are not CTC-graded events. Blood transfusions included both packed red blood cells and whole blood. Laboratory AbnormalitybGemcitabine/Carboplatin (N=175) Carboplatin (N=174) All Grades (%) Grade (%) Grade (%) All Grades (%) Grade (%) Grade (%) Hematologic Neutropenia90422958111 Anemia862267592 Thrombocytopenia7830557101 RBC Transfusion 38--15-- Platelet Transfusions 9--3--Hematopoietic growth factors were administered more frequently in the gemcitabine-containing arm: leukocyte growth factor (24% and 10%) and erythropoiesis-stimulating agent (7% and 3.9%).The following clinically relevant Grade and adverse reactions occurred more frequently in the gemcitabine with carboplatin arm: dyspnea (3.4% versus 2.9%), febrile neutropenia (1.1% versus 0), hemorrhagic event (2.3% versus 1.1 %), motor neuropathy (1.1% versus 0.6%), and rash/desquamation (0.6% versus 0). Breast CancerTables and 10 present the incidence of selected adverse reactions and laboratory abnormalities, occurring in >=10% of gemcitabine-treated patients and at higher incidence in the gemcitabine with paclitaxel arm, reported in randomized trial (Study 2) of gemcitabine with paclitaxel (n=262) compared to paclitaxel alone (n=259) for the first-line treatment of metastatic breast cancer (MBC) in women who received anthracycline-containing chemotherapy in the adjuvant/neoadjuvant setting or for whom anthracyclines were contraindicated [see Clinical Studies (14.2)] Additional clinically significant adverse reactions, occurring in <10% of patients, are provided following Table 10. The requirement for dose reduction of paclitaxel were higher for patients in the gemcitabine/paclitaxel arm (5% versus 2%). The number of paclitaxel doses omitted (<1%), the proportion of patients discontinuing treatment for adverse reactions (7% versus 5%) and the number of treatment-related deaths (1 patient in each arm) were similar between the two arms. Table 9: Selected Adverse Reactions Occurring in Patients Receiving Gemcitabine with Paclitaxel and at Higher Incidence than in Patients Receiving Single Agent Paclitaxel [Between Arm Difference of >=5% (All Grades) or >=2% (Grades 3-4)] in Study a Grade based on National Cancer Institute CTC Version 2.0. Non-laboratory events were graded only if assessed to be possibly drug-related. Adverse-Reactions Gemcitabine/Paclitaxel (N=262) Paclitaxel (N=259) All Grades (%) Grade (%) Grade (%) All Grades (%) Grade (%) Grade (%) Alopecia9014492193 Neuropathy-Sensory645<15830 Nausea50103120 Fatigue406<1281<1 Vomiting29201520 Diarrhea20301320 Anorexia170012<10 Neuropathy-Motor 152<110<10 Stomatitis/Pharyngitis131<18<10 Fever13<10300 Rash/Desquamation11<1<1500 Febrile Neutropenia 65<1210Table 10: Selected Laboratory Abnormalities Occurring in >10% of Patients Receiving Gemcitabine with Paclitaxel and at Higher Incidence than Patients Receiving Single Agent Paclitaxel [Between Arm Difference of >=5% (All Grades) or >=2% (Grades 3-4)] in Study a Grade based on National Cancer Institute CTC Version 2.0. Regardless of causality. Laboratory AbnormalitybGemcitabine/Paclitaxel (N=262) Paclitaxel (N=259) All Grades (%) Grade (%) Grade (%) All Grades (%) Grade (%) Grade (%) Hematologic Anemia6961513<1 Neutropenia6931173147 Thrombocytopenia265<17<1<1Hepatobiliary Increased ALT185<16<10 Increased AST16205<10Clinically relevant Grade or dyspnea occurred with higher incidence in the gemcitabine with paclitaxel arm compared with the paclitaxel arm (1.9% versus 0).Non-Small Cell Lung CancerTables 11 and 12 present the incidence of selected adverse reactions and laboratory abnormalities occurring in >=10% of gemcitabine-treated patients and at higher incidence in the gemcitabine with cisplatin arm, reported in randomized trial (Study 3) of gemcitabine with cisplatin (n=260) administered in 28-day cycles as compared to cisplatin alone (n=262) in patients receiving first-line treatment for locally advanced or metastatic NSCLC [see Clinical Studies (14.3)]. Patients randomized to gemcitabine with cisplatin received median of cycles of treatment and those randomized to cisplatin alone received median of cycles of treatment. In this trial, the requirement for dose adjustments (>90% versus 16%), discontinuation of treatment for adverse reactions (15% versus 8%), and the proportion of patients hospitalized (36% versus 23%) were all higher for patients receiving gemcitabine with cisplatin compared to those receiving cisplatin alone. The incidence of febrile neutropenia (3% versus <1%), sepsis (4% versus 1%), Grade cardiac dysrhythmias (3% versus <1%) were all higher in the gemcitabine with cisplatin arm compared to the cisplatin alone arm. The two-drug combination was more myelosuppressive with (1.5%) possibly treatment-related deaths, including resulting from myelosuppression with infection and one case of renal failure associated with pancytopenia and infection. No deaths due to treatment were reported on the cisplatin arm. Table 11: Selected Adverse Reactions Occurring in >=10% of Patients Receiving Gemcitabine with Cisplatin and at Higher Incidence than in Patients Receiving Single Agent Cisplatin [Between Arm Difference of >=5% (All Grades) or >=2% (Grades 3-4)] in Study a Grade based on National Cancer Institute Common Toxicity Criteria (CTC). Non-laboratory events were graded only if assessed to be possibly drug-related. N=217-253; all Gemcitabine/cisplatin patients with laboratory or non-laboratory data N=213-248; all cisplatin patients with laboratory or non-laboratory data Adverse ReactionsbGemcitabine/Cisplatin Cisplatin All Grades (%)Grade (%)Grade (%)All Grades (%)Grade (%)Grade (%) Nausea 932528720<1 Vomiting78111271109 Alopecia53103300 Neuro Motor351201530 Diarrhea24221300 Neuro Sensory23101810 Infection18321210 Fever1600500 Neuro Cortical1631910 Neuro Mood16101010 Local1500600 Neuro Headache1400700 Stomatitis1410500 Hemorrhage1410400 Hypotension1210710 Rash1100300Table 12: Selected Laboratory Abnormalities Occurring in >10% of Patients Receiving Gemcitabine with Cisplatin and at Higher Incidence than in Patients Receiving Single Agent Cisplatin [Between Arm Difference of >=5% (All Grades) or >=2% (Grades 3-4)] in Study a Grade based on National Cancer Institute CTC. Regardless of causality. N=217-253; all gemcitabine/cisplatin patients with laboratory or non-laboratory data N=213-248; all cisplatin patients with laboratory or non-laboratory data Percent of patients receiving transfusions. Percent transfusions are not CTC-graded events. Laboratory AbnormalitybGemcitabine/Cisplatin Cisplatin All Grades (%) Grade (%) Grade (%) All Grades (%) Grade (%) Grade (%) Hematologic Anemia892236761 Thrombocytopenia8525251331 Neutropenia7922352031 Lymphopenia75251851125 RBC Transfusions 39--13-- Platelet Transfusions 21--<1--Hepatic Increased Transaminases22211010 Increased Alkaline Phosphatase19101300Renal Increased Creatinine384<1312<1 Proteinuria23001800 Hematuria15001300Other Laboratory Hyperglycemia30402330 Hypomagnesemia30431720 Hypocalcemia182070<1Tables 13 and 14 present the incidence of selected adverse reactions and laboratory abnormalities occurring in >=10% of gemcitabine-treated patients and at higher incidence in the gemcitabine with cisplatin arm, reported in randomized trial (Study 4) of gemcitabine with cisplatin (n=69) administered in 21-day cycles as compared to etoposide with cisplatin (n=66) in patients receiving first-line treatment for locally advanced or metastatic NSCLC [see Clinical Studies (14.3)]. Additional clinically significant adverse reactions are provided following Table 14. Patients in the gemcitabine/cisplatin (GC) arm received median of cycles and those in the etoposide/cisplatin (EC) arm received median of cycles. The majority of patients receiving more than one cycle of treatment required dose adjustments; 81% in the GC arm and 68% in the EC arm. The incidence of hospitalizations for adverse reactions was 22% in the GC arm and 27% in the EC arm. The proportion of patients who discontinued treatment for adverse reactions was higher in the GC arm (14% versus 8%). The proportion of patients who were hospitalized for febrile neutropenia was lower in the GC arm (7% versus 12%). There was one death attributed to treatment, patient with febrile neutropenia and renal failure, which occurred in the GC arm. Table 13: Selected Adverse Reactions in Patients Receiving Gemcitabine with Cisplatin in Study a Grade based on criteria from the WHO. Non-laboratory events were graded only if assessed to be possibly drug-related. Pain data were not collected. N=67-69; all Gemcitabine/cisplatin patients with non-laboratory data. N=57-63; all Etoposide/cisplatin patients with non-laboratory data. Flu-like syndrome and edema were not graded. Adverse ReactionsbGemcitabine/Cisplatin Etoposide/Cisplatin All Grades (%)Grade (%)Grade (%)All Grades (%)Grade (%)Grade (%)Nausea and Vomiting9635486197Alopecia7713092510Paresthesias38001620Infection28312180Stomatitis20401820Diarrhea14111302Edemae12--2--Rash1000300Hemorrhage903303Fever600300Somnolence300320Flu-like Syndromee3--0--Dyspnea101300Table 14: Selected Laboratory Abnormalities Occurring in Patients Receiving Gemcitabine with Cisplatin in Study a Grade based on criteria from the WHO. Regardless of causality. N=67-69; all Gemcitabine for Injection /cisplatin patients with laboratory or non-laboratory data. N=57-63; all Etoposide/cisplatin patients with laboratory or non-laboratory data. WHO grading scale not applicable to proportion of patients with transfusions. Laboratory AbnormalitybGemcitabine/Cisplatin Etoposide/Cisplatin All Grades (%) Grade (%) Grade (%) All Grades (%) Grade (%) Grade (%) Hematologic Anemia8822077132 Neutropenia883628872056 Thrombocytopenia8139164585 RBC Transfusions 29--21-- Platelet Transfusions 3--8--Hepatic Increased Alkaline Phosphatase16001100 Increased ALT6001200 Increased AST3001100Renal Hematuria22001000 Proteinuria1200500 Increased BUN600400 Increased Creatinine200200. Transfusion requirements: Red blood cell transfusions (19%); platelet transfusions (<1%). Edema: Edema (13%), peripheral edema (20%), generalized edema (<1%) Flu-like symptoms: Fever, asthenia, anorexia, headache, cough, chills, myalgia, asthenia insomnia, rhinitis, sweating and/or malaise (19%) Infection: Sepsis (<1%). Extravasation: Injection-site reactions (4%). Allergic: Bronchospasm (<2%); anaphylactoid reactions. 6.2 Postmarketing Experience. The following adverse reactions have been identified during postapproval use of gemcitabine. Because these reactions are reported voluntarily from population of uncertain size, it is not always possible to reliably estimate their frequency or establish causal relationship to drug exposure. Blood and lymphatic system: Thrombotic microangiopathy (TMA) Cardiovascular: Congestive heart failure, myocardial infarction, arrhythmias, supraventricular arrhythmias Vascular: Peripheral vasculitis, gangrene, capillary leak syndrome Skin: Cellulitis, pseudocellulitis, severe skin reactions, including desquamation and bullous skin eruptions Hepatic: Hepatic failure, hepatic veno-occlusive disease Pulmonary: Interstitial pneumonitis, pulmonary fibrosis, pulmonary edema, adult respiratory distress syndrome (ARDS), pulmonary eosinophilia Nervous System: Posterior reversible encephalopathy syndrome (PRES) Blood and lymphatic system: Thrombotic microangiopathy (TMA) Cardiovascular: Congestive heart failure, myocardial infarction, arrhythmias, supraventricular arrhythmias Vascular: Peripheral vasculitis, gangrene, capillary leak syndrome Skin: Cellulitis, pseudocellulitis, severe skin reactions, including desquamation and bullous skin eruptions Hepatic: Hepatic failure, hepatic veno-occlusive disease Pulmonary: Interstitial pneumonitis, pulmonary fibrosis, pulmonary edema, adult respiratory distress syndrome (ARDS), pulmonary eosinophilia Nervous System: Posterior reversible encephalopathy syndrome (PRES).

CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY SECTION.

13.1Carcinogenesis, Mutagenesis, Impairment of Fertility. Long-term animal studies to evaluate the carcinogenic potential of gemcitabine have not been conducted. Gemcitabine was mutagenic in an in vitro mouse lymphoma (L5178Y) assay and was clastogenic in an in vivo mouse micronucleus assay. Gemcitabine intraperitoneal doses of 0.5 mg/kg/day [about 1/700 the 1000 mg/m clinical dose based on body surface area (BSA)] in male mice resulted in moderate to severe hypospermatogenesis, decreased fertility, and decreased implantations. In female mice, fertility was not affected but maternal toxicities were observed at 1.5 mg/kg/day administered intravenously (about 1/200 the 1000 mg/m clinical dose based on BSA) and fetotoxicity or embryolethality was observed at 0.25 mg/kg/day administered intravenously (about 1/1300 the 1000 mg/m2 clinical dose based on BSA).

CLINICAL PHARMACOLOGY SECTION.

12 CLINICAL PHARMACOLOGY. 12.1 Mechanism of Action. Gemcitabine kills cells undergoing DNA synthesis and blocks the progression of cells through the G1/S-phase boundary. Gemcitabine is metabolized by nucleoside kinases to diphosphate (dFdCDP) and triphosphate (dFdCTP) nucleosides. Gemcitabine diphosphate inhibits ribonucleotide reductase, an enzyme responsible for catalyzing the reactions that generate deoxynucleoside triphosphates for DNA synthesis, resulting in reductions in deoxynucleotide concentrations, including dCTP. Gemcitabine triphosphate competes with dCTP for incorporation into DNA. The reduction in the intracellular concentration of dCTP by the action of the diphosphate enhances the incorporation of gemcitabine triphosphate into DNA (self-potentiation). After the gemcitabine nucleotide is incorporated into DNA, only one additional nucleotide is added to the growing DNA strands, which eventually results in the initiation of apoptotic cell death.. 12.3 Pharmacokinetics. The pharmacokinetics of gemcitabine were examined in 353 patients, with various solid tumors. Pharmacokinetic parameters were derived using data from patients treated for varying durations of therapy given weekly with periodic rest weeks and using both short infusions (<70 minutes) and long infusions (70 to 285 minutes). The total gemcitabine dose varied from 500 mg/m to 3600 mg/m 2. Distribution The volume of distribution was increased with infusion length. Volume of distribution of gemcitabine was 50 L/m following infusions lasting 70 minutes. For long infusions, the volume of distribution rose to 370 L/m 2. Gemcitabine pharmacokinetics are linear and are described by 2-compartment model. Population pharmacokinetic analyses of combined single and multiple dose studies showed that the volume of distribution of gemcitabine was significantly influenced by duration of infusion and sex. Gemcitabine plasma protein binding is negligible. Elimination MetabolismThe active metabolite, gemcitabine triphosphate, can be extracted from peripheral blood mononuclear cells. The half-life of the terminal phase for gemcitabine triphosphate from mononuclear cells ranges from 1.7 to 19.4 hours.. ExcretionGemcitabine disposition was studied in patients who received single 1000 mg/m of radiolabeled drug as 30-minute infusion. Within one week, 92% to 98% of the dose was recovered, almost entirely in the urine. Gemcitabine (<10%) and the inactive uracil metabolite, 2-deoxy-2,2-difluorouridine (dFdU) accounted for 99% of the excreted dose. The metabolite dFdU is also found in plasma. Specific PopulationsGeriatric PatientsClearance of gemcitabine was affected by age. The lower clearance in geriatric patients results in higher concentrations of gemcitabine for any given dose. Differences in either clearance or volume of distribution based on patient characteristics or the duration of infusion result in changes in half-life and plasma concentrations. Table 15 shows plasma clearance and half-life of gemcitabine following short infusions for typical patients by age and sex. Table 15: Gemcitabine Clearance and Half-Life for the Typical Patienta Half-life for patients receiving <70 minute infusion. AgeClearance Men (L/hr/m 2) Clearance Women (L/hr/m 2) Half-Life Men (min) Half-Life Women (min) 2992.269.442494575.757.048576555.141.561737940.730.77994Gemcitabine half-life for short infusions ranged from 42 to 94 minutes and for long infusions varied from 245 to 638 minutes, depending on age and sex, reflecting greatly increased volume of distribution with longer infusions. Male and Female PatientsFemales have lower clearance and longer half lives than male patients as described in Table 15. Patients with Renal ImpairmentNo clinical studies have been conducted with gemcitabine in patients with decreased renal function.Patients with Hepatic ImpairmentNo clinical studies have been conducted with gemcitabine in patients with decreased hepatic function.Drug Interaction StudiesWhen gemcitabine (1250 mg/m on Days and 8) and cisplatin (75 mg/m on Day 1) were administered in patients with NSCLC, the clearance of gemcitabine on Day was 128 L/hr/m and on Day was 107 L/hr/m 2. Data from patients with NSCLC demonstrate that gemcitabine and carboplatin given in combination does not alter the pharmacokinetics of gemcitabine or carboplatin compared to administration of either single agent; however, due to wide confidence intervals and small sample size, interpatient variability may be observed. Data from metastatic breast cancer patients shows that gemcitabine has little or no effect on the pharmacokinetics (clearance and half-life) of paclitaxel and paclitaxel has little or no effect on the pharmacokinetics of gemcitabine.

CLINICAL STUDIES SECTION.

14 CLINICAL STUDIES. 14.1 Ovarian Cancer. The efficacy of gemcitabine was evaluated in randomized trial (Study 1) conducted in women with advanced ovarian cancer that had relapsed at least months after first-line platinum-based therapy. Patients were randomized to receive either gemcitabine 1000 mg/m on Days and of each 21-day cycle with carboplatin AUC on Day after gemcitabine administration (n=178) or carboplatin AUC on Day of each 21-day cycle (n=178). The major efficacy outcome measure was progression free survival (PFS). total of 356 patients were enrolled. Demographics and baseline characteristics are shown in Table 16 Efficacy results are presented in Table 17 and Figure 1. The addition of gemcitabine to carboplatin resulted in statistically significant improvements in PFS and overall response rate. Approximately 75% of patients in each arm received additional chemotherapy for disease progression; 13 of 120 patients in the carboplatin alone arm received gemcitabine for treatment of disease progression. There was no significant difference in overall survival between the treatment arms. Table 16: Baseline Demographics and Clinical Characteristics for Study a patients on gemcitabine with carboplatin arm and patients on carboplatin arm had no baseline Eastern Cooperative Oncology Group (ECOG) performance status. 2 patients on gemcitabine with carboplatin arm and patient on carboplatin arm had platinum-free interval <6 months. Gemcitabine /Carboplatin (N=178) Carboplatin (N=178) Median age, years Range 59 36 to 78 58 21 to 81 Baseline ECOG performance status 0-1 94%95%Disease Status Evaluable Bidimensionally measurable 8% 92% 3% 96% Platinum-free interval 6-12 months >12 months 40% 59% 40% 60% First-line therapy Platinum-taxane combination Platinum-non-taxane combination Platinum monotherapy 70% 29% 1% 71% 28% 1% Table 17: Efficacy Results in Study a CI=confidence interval. Log rank, unadjusted. Chi square. CR=Complete response. PR with PRNM=Partial response with partial response, non-measurable disease. Independently reviewed cohort gemcitabine/carboplatin (n=121), carboplatin (n=101); independent reviewers unable to measure disease detected by sonography or physical exam. Efficacy ParameterGemcitabine /Carboplatin (N=178) Carboplatin (N=178) Progression-Free Survival Median (95% CI a) in months 8.6 (8.0, 9.7)5.8 (5.2, 7.1) Hazard Ratio (95% CI)0.72 (0.57, 0.90) p-value p=0.0038Overall Survival Median (95% CI) in months18.0 (16.2, 20.3)17.3 (15.2, 19.3) Hazard Ratio (95% CI)0.98 (0.78, 1.24) p-value p=0.8977Overall Response Rate by Investigator Review47.2%30.9% p-value p=0.0016 CR 14.6%6.2% PR with PRNM 32.6%24.7%Overall Response Rate by Independent Review 46.3%35.6% p-value p=0.11 CR 9.1%4.0% PR with PRNM 37.2%31.7%Figure 1: Kaplan-Meier Curves for Progression-Free Survival in Study 1. Gemcitabine for Injection Figure 1. 14.2 Breast Cancer. The efficacy of gemcitabine was evaluated in multinational, randomized, open-label trial (Study 2) conducted in women receiving initial treatment for metastatic breast cancer and who have received prior adjuvant/neoadjuvant anthracycline chemotherapy unless clinically contraindicated. Patients were randomized to receive either gemcitabine 1250 mg/m on Days and of each 21-day cycle with paclitaxel 175 mg/m administered on Day before gemcitabine administration (n=267) or paclitaxel 175 mg/m on Day of each 21-day cycle (n=262). The major efficacy outcome measure was time to documented disease progression. total of 529 patients were enrolled. Demographic and baseline characteristics were similar between treatment arms Table 18). Efficacy results are presented in Table 19 and Figure 2. The addition of gemcitabine to paclitaxel resulted in statistically significant improvement in time to documented disease progression and overall response rate compared to paclitaxel alone. There was no significant difference in overall survival. Table 18: Baseline Demographics and Clinical Characteristics for Study 2a Karnofsky Performance Status. Gemcitabine/Paclitaxel (N=267) Paclitaxel (N=262) Median age (years) 53 52 Range 26 to 83 26 to 75Metastatic disease97%97%Baseline KPS >=90 70%74%Number of tumor sites 1-2 57% 59% >=3 43% 41%Visceral disease73%73%Prior anthracycline97%96%Table 19: Efficacy Results in Study 2a These represent reconciliation of investigator and Independent Review Committee assessments according to predefined algorithm. Based on the ITT population. Efficacy Parameter Gemcitabine/Paclitaxel (N=267) Paclitaxel (N=262) Time to Documented Disease Progression Median (95% CI) in months 5.2 (4.2, 5.6) 2.9 (2.6, 3.7) Hazard Ratio (95% CI) 0.650 (0.524, 0.805) p-value p<0.0001Overall Survival Median (95% CI) in months 18.6 (16.5, 20.7) 15.8 (14.1, 17.3) Hazard Ratio (95% CI) 0.86 (0.71, 1.04) p-value Not Significant Overall Response Rate 40.8% 22.1% (95% CI) (34.9, 46.7) (17.1, 27.2) p-value p<0.0001Figure 2: Kaplan-Meier Curves for Time to Documented Disease Progression in Study 2. Gemcitabine for Injection Figure 2. 14.3 Non-Small Cell Lung Cancer The efficacy of gemcitabine was evaluated in two randomized, multicenter trials.Study 3: 28-Day ScheduleA multinational, randomized trial (Study 3) compared gemcitabine with cisplatin to cisplatin alone in the treatment of patients with inoperable Stage IIIA, IIIB, or IV NSCLC who had not received prior chemotherapy. Patients were randomized to receive either gemcitabine 1000 mg/m on Days 1, 8, and 15 of each 28-day cycle with cisplatin 100 mg/m on Day after gemcitabine administration (N=260) or cisplatin 100 mg/m on Day of each 28-day cycle (N=262). The major efficacy outcome measure was overall survival. total of 522 patients were enrolled. Demographics and baseline characteristics (Table 20) were similar between arms with the exception of histologic subtype of NSCLC, with 48% of patients on the cisplatin arm and 37% of patients on the gemcitabine with cisplatin arm having adenocarcinoma. Efficacy results are presented in Table 21 and Figure 3. Study 4: 21-Day Schedule randomized (1:1), multicenter trial (Study 4) was conducted in patients with Stage IIIB or IV NSCLC. Patients were randomized to receive either gemcitabine 1250 mg/m2 on Days and of each 21-day cycle with cisplatin 100 mg/m on Day after gemcitabine administration or etoposide 100 mg/m intravenously on Days 1, 2, and with cisplatin 100 mg/m on Day of each 21 -day cycle. The major efficacy outcome measure was response rate. total of 135 patients were enrolled. Demographics and baseline characteristics are summarized in Table 20 Efficacy results are presented in Table 21. There was no significant difference in survival between the two treatment arms. The median survival was 8.7 months for the gemcitabine with cisplatin arm versus months for the etoposide with cisplatin arm. Median time to disease progression for the gemcitabine with cisplatin arm was months compared to 4.1 months on the etoposide with cisplatin arm (Log rank p=0.015, two-sided). The objective response rate for the gemcitabine with cisplatin arm was 33% compared to 14% on the etoposide with cisplatin arm (Fishers Exact p=0.01, two-sided). Table 20: Baseline Demographics and Clinical Characteristics for Studies and 4a N/A Not applicable. Karnofsky Performance Status. Trial28-day Schedule (Study 3)21-day Schedule (Study 4)Gemcitabine/Cisplatin (N=260)Cisplatin (N=262)Gemcitabine/Cisplatin (N=69)Etoposide/ Cisplatin(N=66)Male Median age, years Range 70% 62 36 to 88 71% 63 35 to 79 93% 58 33 to 76 92% 60 35 to 75 Stage IIIA Stage IIIB Stage IV 7% 26% 67% 7% 23% 70% N/A 48% 52% N/A 52% 49% Baseline KPS 70 to 80 Baseline KPS 90 to 100 41% 57% 44% 55% 45% 55% 52% 49% Table 21: Efficacy Results for Studies and 4a CI=confidence intervals. p-value two-sided Fishers Exact test for difference in binomial proportions; log rank test for time-to-event analyses. Trial28-day Schedule (Study 3) 21-day Schedule (Study 4)Efficacy ParameterGemcitabine/Cisplatin (N=260)Cisplatin (N=262)Gemcitabine/ Cisplatin (N=69)Etoposide/ Cisplatin (N=66)SurvivalMedian (95% CI a) in months 9.0 (8.2, 11.0)7.6 (6.6, 8.8)8.7 (7.8, 10.1)7.0 (6.0, 9.7)p-value p=0.008p=0.18Time to Disease ProgressionMedian (95% CI a) in months 5.2 (4.2, 5.7)3.7 (3.0, 4.3)5.0 (4.2, 6.4)4.1 (2.4, 4.5)p-value p=0.009p=0.015Tumor Response26%10%33%14%p-value p<0.0001p=0.01Figure 3: Kaplan-Meier Curves for Overall Survival in Study 3. Gemcitabine for Injection Figure 3. 14.4Pancreatic Cancer. The efficacy of gemcitabine was evaluated in two trials (Studies and 6), randomized, single-blind, two-arm, active-controlled trial (Study 5) conducted in patients with locally advanced or metastatic pancreatic cancer who had received no prior chemotherapy and in single-arm, open-label, multicenter trial (Study 6) conducted in patients with locally advanced or metastatic pancreatic cancer previously treated with fluorouracil or fluorouracil-containing regimen. In Study 5, patients were randomized to receive either gemcitabine 1000 mg/m intravenously over 30 minutes once weekly for weeks followed by one-week rest, then once weekly for consecutive weeks every 28-days in subsequent cycles (n=63) or fluorouracil 600 mg/m intravenously over 30 minutes once weekly (n=63). In Study 6, all patients received gemcitabine 1000 mg/m intravenously over 30 minutes once weekly for weeks followed by one-week rest, then once weekly for consecutive weeks every 28-days in subsequent cycles. The major efficacy outcome measure in both trials was clinical benefit response. patient was considered to have had clinical benefit response if either of the following occurred: The patient achieved >=50% reduction in pain intensity (Memorial Pain Assessment Card) or analgesic consumption, or 20-point or greater improvement in performance status (Karnofsky Performance Status) for period of at least consecutive weeks, without showing any sustained worsening in any of the other parameters. Sustained worsening was defined as consecutive weeks with either any increase in pain intensity or analgesic consumption or 20-point decrease in performance status occurring during the first 12 weeks of therapy. OR The patient was stable on all of the aforementioned parameters, and showed marked, sustained weight gain (>=7% increase maintained for >=4 weeks) not due to fluid accumulation. Study enrolled 126 patients. Demographics and baseline characteristics were similar between the arms (Table 22). The efficacy results are shown in Table 23 and Figure 4. Patients treated with gemcitabine had statistically significant increases in clinical benefit response, survival, and time to disease progression compared to those randomized to receive fluorouracil. No confirmed objective tumor responses were observed in either treatment arm. Table 22: Baseline Demographics and Clinical Characteristics for Study 5a Karnofsky Performance Status. Gemcitabine (N=63) Fluorouracil (N=63) Male54%54%Median age, years62 61 Range37 to 7936 to 77Stage IV disease71%76%Baseline KPS <=70 70%68%Table 23: Efficacy Results in Study 5a p-value for clinical benefit response calculated using the two-sided test for difference in binomial proportions. All other p-values are calculated using log rank test. Efficacy ParameterGemcitabine (N= 63) Fluorouracil (N= 63) Clinical Benefit Response22.2%4.8%p-value p=0.004Overall Survival Median (95% CI) in months5.7 (4.7, 6.9)4.2 (3.1, 5.1) p-value p=0.0009Time to Disease Progression Median (95% CI) in months 2.1 (1.9, 3.4)0.9 (0.9, 1.1) p-value p=0.0013Figure 4: Kaplan-Meier Curves for Overall Survival in Study 5. The patient achieved >=50% reduction in pain intensity (Memorial Pain Assessment Card) or analgesic consumption, or 20-point or greater improvement in performance status (Karnofsky Performance Status) for period of at least consecutive weeks, without showing any sustained worsening in any of the other parameters. Sustained worsening was defined as consecutive weeks with either any increase in pain intensity or analgesic consumption or 20-point decrease in performance status occurring during the first 12 weeks of therapy. OR The patient was stable on all of the aforementioned parameters, and showed marked, sustained weight gain (>=7% increase maintained for >=4 weeks) not due to fluid accumulation. Gemcitabine for Injection Figure 4.

CONTRAINDICATIONS SECTION.

4 CONTRAINDICATIONS. Gemcitabine for Injection is contraindicated in patients with known hypersensitivity to gemcitabine. Reactions include anaphylaxis [see Adverse Reactions (6.1)]. Patients with known hypersensitivity to gemcitabine.

DESCRIPTION SECTION.

11 DESCRIPTION. Gemcitabine is nucleoside metabolic inhibitor. Gemcitabine hydrochloride is 2-deoxy-2,2-difluorocytidine monohydrochloride (-isomer) with the following structural formula:The empirical formula for gemcitabine hydrochloride is 9H 11F 2N 3O o HCl. It has molecular weight of 299.66 g/mol. Gemcitabine hydrochloride is soluble in water, slightly soluble in methanol, and practically insoluble in ethanol and polar organic solvents. Gemcitabine for Injection is sterile white to off-white lyophilized powder and available as 200 mg, g and g single-dose vials for intravenous use only. Each 200 mg vial contains 200 mg gemcitabine (equivalent to 227.7 mg gemcitabine hydrochloride), 200 mg mannitol and 12.5 mg sodium acetate. Each g vial contains g gemcitabine (equivalent to 1.139 gemcitabine hydrochloride), g mannitol and 62.5 mg sodium acetate. Each g vial contains g gemcitabine (equivalent to 2.277 gemcitabine hydrochloride), g mannitol and 125 mg sodium acetate. Hydrochloric acid and/or sodium hydroxide may have been added for pH adjustment.. Gemcitabine for Injection Chemical Structure.

DOSAGE & ADMINISTRATION SECTION.

2 DOSAGE AND ADMINISTRATION. Gemcitabine for Injection is for intravenous use only.Ovarian Cancer: 1000 mg/m over 30 minutes on Days and of each 21-day cycle 2.1) Breast Cancer: 1250 mg/m over 30 minutes on Days and of each 21day cycle 2.2) Non-Small Cell Lung Cancer: 1000 mg/m over 30 minutes on Days 1, 8, and 15 of each 28-day cycle or 1250 mg/m over 30 minutes on Days and of each 21-day cycle 2.3) Pancreatic Cancer: 1000 mg/m over 30 minutes once weekly for the first weeks, then one week rest, then once weekly for weeks of each 28-day cycle 2.4)) Ovarian Cancer: 1000 mg/m over 30 minutes on Days and of each 21-day cycle 2.1) Breast Cancer: 1250 mg/m over 30 minutes on Days and of each 21day cycle 2.2) Non-Small Cell Lung Cancer: 1000 mg/m over 30 minutes on Days 1, 8, and 15 of each 28-day cycle or 1250 mg/m over 30 minutes on Days and of each 21-day cycle 2.3) Pancreatic Cancer: 1000 mg/m over 30 minutes once weekly for the first weeks, then one week rest, then once weekly for weeks of each 28-day cycle 2.4)) 2.1 Ovarian Cancer. Recommended Dose and Schedule The recommended dosage of Gemcitabine for Injection is 1000 mg/m intravenously over 30 minutes on Days and of each 21-day cycle in combination with carboplatin AUC administered intravenously on Day after Gemcitabine for Injection administration. Refer to carboplatin prescribing information for additional information. Dosage ModificationsRecommended Gemcitabine for Injection dosage modifications for myelosuppression are described in Table and Table [see Warnings and Precautions 5.2)]. Refer to the recommended dosage modifications for non-hematologic adverse reactions [see Dosage and Administration (2.5)]. Table 1: Recommended Dosage Modifications for Gemcitabine for Injection for Myelosuppression on Day of Treatment in Ovarian CancerTreatment DayAbsolute Neutrophil Count (x 10 6/L) Platelet Count (x 10 6/L) Dosage ModificationDay 1Greater than or equal to 1500AndGreater than or equal to 100,000NoneLess than 1500OrLess than 100,000Delay Treatment CycleDay 8Greater than or equal to 1500AndGreater than or equal to 100,000None1000 to 1499Or75,000 to 99,99950% of full doseLess than 1000OrLess than 75,000HoldTable 2: Recommended Dosage Modifications for Gemcitabine for Injection for Myelosuppression in Previous Cycle in Ovarian CancerOccurrenceMyelosuppression During Treatment CycleDosage Modification Initial OccurrenceAbsolute neutrophil count less than 500 10 6/L for more than days or Absolute neutrophil count less than 100 10 6/L for more than days or Febrile neutropenia orPlatelets less than 25,000x10 6/L or Cycle delay for more than one week due to toxicity Permanently reduce Gemcitabine for Injection to 800 mg/m on Days and Subsequent OccurrenceIf any of the above toxicities occur after the initial dose reduction: Permanently reduce Gemcitabine for Injection to 800 mg/m on Day only Absolute neutrophil count less than 500 10 6/L for more than days or Absolute neutrophil count less than 100 10 6/L for more than days or Febrile neutropenia or. Platelets less than 25,000x10 6/L or Cycle delay for more than one week due to toxicity 2.2 Breast Cancer. Recommended Dose and Schedule The recommended dosage of Gemcitabine for Injection is 1250 mg/m intravenously over 30 minutes on Days and of each 21-day cycle in combination with paclitaxel 175 mg/m administered as 3-hour intravenous infusion on Day before Gemcitabine for Injection administration. Refer to paclitaxel prescribing information for additional information. Dosage ModificationsRecommended Gemcitabine for Injection dosage modifications for myelosuppression are described in Table [ see Warnings and Precautions 5.2) ]. Refer to the recommended dosage modifications for non-hematologic adverse reactions [see Dosage and Administration 2.5)]. Table 3: Recommended Dosage Modifications for Gemcitabine for Injection for Myelosuppression on Day of Treatment in Breast Cancer Treatment DayAbsolute Neutrophil Count (x 10 6/L) Platelet Count (x10 6/L) Dosage ModificationDay 1Greater than or equal to 1500AndGreater than or equal to 100,000NoneLess than 1500OrLess than 100,000HoldDay 8Greater than or equal to 1200AndGreater than 75,000None1000 to 1199Or50,000 to 75,00075% of full dose700 to 999AndGreater than or equal to 50,00050% of full doseLess than 700OrLess than 50,000Hold. 2.3 Non-Small Cell Lung Cancer. Recommended Dose and Schedule 28-day schedule The recommended dosage of Gemcitabine for Injection is 1000 mg/m intravenously over 30 minutes on Days 1, 8, and 15 of each 28day cycle in combination with cisplatin 100 mg/m administered intravenously on Day after Gemcitabine for Injection administration. 21-day schedule The recommended dosage of Gemcitabine for Injection is 1250 mg/m intravenously over 30 minutes on Days and of each 21-day cycle in combination with cisplatin 100 mg/m administered intravenously on Day after Gemcitabine for Injection administration. Refer to cisplatin prescribing information for additional information.Dosage ModificationsRecommended dosage modifications for Gemcitabine for Injection myelosuppression are described in Table [see Warnings and Precautions 5.2)]. Refer to the recommended dosage modifications for non-hematologic adverse reactions [see Dosage and Administration 2.5)]. 2.4 Pancreatic Cancer. Recommended Dose and ScheduleThe recommended dosage of Gemcitabine for Injection is 1000 mg/m intravenously over 30 minutes. The recommended treatment schedule is as follows: Weeks to 8: weekly dosing for the first weeks followed by one week rest.After week 8: weekly dosing on Days 1, 8, and 15 of each 28-day cycle. Dosage Modifications Recommended dosage modifications for Gemcitabine for Injection for myelosuppression are described in Table [see Warnings and Precautions 5.2)]. Refer to the recommended dosage modifications for non-hematologic adverse reactions [see Dosage and Administration (2.5)]. Table 4: Recommended Dosage Modifications for Gemcitabine for Injection for Myelosuppression in Pancreatic Cancer and Non-Small Cell Lung CancerAbsolute Neutrophil Count (x 10 6/L) Platelet Count (x 10 6/L) Dosage ModificationGreater than or equal to 1000AndGreater than or equal to 100,000None500 to 999Or50,000 to 99,99975% of full doseLess than 500OrLess than 50,000Hold. Weeks to 8: weekly dosing for the first weeks followed by one week rest.. After week 8: weekly dosing on Days 1, 8, and 15 of each 28-day cycle. 2.5 Dosage Modifications for Non-Hematologic Adverse Reactions Permanently discontinue Gemcitabine for Injection for any of the following: Unexplained dyspnea or evidence of severe pulmonary toxicity [see Warnings and Precautions (5.3)] Hemolytic uremic syndrome (HUS) or severe renal impairment [see Warnings and Precautions (5.4)] Severe hepatic toxicity [see Warnings and Precautions (5.5)] Capillary leak syndrome (CLS) [see Warnings and Precautions (5.8)] Posterior reversible encephalopathy syndrome (PRES) [see Warnings and Precautions (5.9)] Withhold Gemcitabine for Injection or reduce dose by 50% for other Grade or non-hematological adverse reactions until resolved. No dose modifications are recommended for alopecia, nausea, or vomiting. Unexplained dyspnea or evidence of severe pulmonary toxicity [see Warnings and Precautions (5.3)] Hemolytic uremic syndrome (HUS) or severe renal impairment [see Warnings and Precautions (5.4)] Severe hepatic toxicity [see Warnings and Precautions (5.5)] Capillary leak syndrome (CLS) [see Warnings and Precautions (5.8)] Posterior reversible encephalopathy syndrome (PRES) [see Warnings and Precautions (5.9)] 2.6 Preparation. Gemcitabine for Injection vials contain no antimicrobial preservatives and are intended for single use only. Gemcitabine for Injection is cytotoxic drug. Follow applicable special handling and disposal procedures. Exercise caution and wear gloves when preparing Gemcitabine for Injection solutions. Immediately wash the skin thoroughly or rinse the mucosa with copious amounts of water if Gemcitabine for Injection contacts the skin or mucus membranes. Death has occurred in animal studies due to dermal absorption. Reconstitute the 200 mg vial with mL and the g vial with 25 mL and the g vial with 50 mL of 0.9% Sodium Chloride Injection, USP to yield Gemcitabine for Injection concentration of 38 mg/mL. Reconstituted Gemcitabine for Injection is clear, colorless solution. Visually inspect reconstituted product for particulate matter and discoloration. Discard if particulate matter or discoloration is observed. Withdraw the calculated dose from the vial and discard any unused portion. Prior to administration, dilute the reconstituted solution with 0.9% Sodium Chloride Injection, USP to minimum final concentration of at least 0.1 mg/mL. Store Gemcitabine for Injection solutions (reconstituted and diluted) at controlled room temperature of 20C to 25C (68F to 77F). Do not refrigerate as crystallization can occur. Discard Gemcitabine for Injection solutions if not used within 24 hours after reconstitution. No incompatibilities have been observed with infusion bottles or polyvinyl chloride bags and administration sets. Gemcitabine for Injection vials contain no antimicrobial preservatives and are intended for single use only. Gemcitabine for Injection is cytotoxic drug. Follow applicable special handling and disposal procedures. . Exercise caution and wear gloves when preparing Gemcitabine for Injection solutions. Immediately wash the skin thoroughly or rinse the mucosa with copious amounts of water if Gemcitabine for Injection contacts the skin or mucus membranes. Death has occurred in animal studies due to dermal absorption. Reconstitute the 200 mg vial with mL and the g vial with 25 mL and the g vial with 50 mL of 0.9% Sodium Chloride Injection, USP to yield Gemcitabine for Injection concentration of 38 mg/mL. Reconstituted Gemcitabine for Injection is clear, colorless solution. Visually inspect reconstituted product for particulate matter and discoloration. Discard if particulate matter or discoloration is observed. Withdraw the calculated dose from the vial and discard any unused portion. Prior to administration, dilute the reconstituted solution with 0.9% Sodium Chloride Injection, USP to minimum final concentration of at least 0.1 mg/mL. Store Gemcitabine for Injection solutions (reconstituted and diluted) at controlled room temperature of 20C to 25C (68F to 77F). Do not refrigerate as crystallization can occur. Discard Gemcitabine for Injection solutions if not used within 24 hours after reconstitution. No incompatibilities have been observed with infusion bottles or polyvinyl chloride bags and administration sets.

DOSAGE FORMS & STRENGTHS SECTION.

3 DOSAGE FORMS AND STRENGTHS For injection: 200 mg gemcitabine or g gemcitabine or g gemcitabine as sterile white to off-white lyophilized powder in single-dose vial for reconstitution. For injection: 200 mg or gram or gram lyophilized powder in single-dose vials for reconstitution. 3).

GERIATRIC USE SECTION.

8.5 Geriatric Use. In clinical studies which enrolled 979 patients with various malignancies who received single agent gemcitabine, no overall differences in safety were observed between patients aged 65 and older and younger patients, with the exception of higher rate of Grade 3-4 thrombocytopenia in older patients as compared to younger patients. In randomized trial in women with ovarian cancer (Study 1), 175 women received gemcitabine with carboplatin, of which 29% were age 65 years or older. Similar effectiveness was observed between older and younger women. There was significantly higher Grade 3-4 neutropenia in women 65 years of age or older [see Dosage and Administration 2.1) ]. Gemcitabine clearance is affected by age; however, there are no recommended dose adjustments based on patients age [see Clinical Pharmacology 12.3)].

HOW SUPPLIED SECTION.

16 HOW SUPPLIED/STORAGE AND HANDLING. Gemcitabine for Injection is sterile white to off-white lyophilized powder available in single-dose vials individually packaged in carton containing 200 mg, 1g or g gemcitabine:200 mg vial: NDC 16729-092-03 (No. 092)1 vial: NDC 16729-117-11 (No. 117) g vial: NDC 16729-118-38 (No. 118)Gemcitabine for Injection is cytotoxic drug. Follow applicable special handling and disposal procedures. Store at controlled room temperature 20C to 25C (68F to 77F); excursions permitted between 15C and 30C (59F and 86F) [see USP Controlled Room Temperature].. 200 mg vial: NDC 16729-092-03 (No. 092). g vial: NDC 16729-117-11 (No. 117) 2 vial: NDC 16729-118-38 (No. 118).

INDICATIONS & USAGE SECTION.

1 INDICATIONS AND USAGE. Gemcitabine for Injection is nucleoside metabolic inhibitor indicated:in combination with carboplatin, for the treatment of advanced ovarian cancer that has relapsed at least months after completion of platinum-based therapy. 1.1) in combination with paclitaxel, for first-line treatment of metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated. 1.2) in combination with cisplatin for the treatment of non-small cell lung cancer. 1.3) as single agent for the treatment of pancreatic cancer. 1.4) in combination with carboplatin, for the treatment of advanced ovarian cancer that has relapsed at least months after completion of platinum-based therapy. 1.1) in combination with paclitaxel, for first-line treatment of metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated. 1.2) in combination with cisplatin for the treatment of non-small cell lung cancer. 1.3) as single agent for the treatment of pancreatic cancer. 1.4) 1.1 Ovarian Cancer. Gemcitabine for Injection in combination with carboplatin is indicated for the treatment of patients with advanced ovarian cancer that has relapsed at least months after completion of platinum-based therapy.. 1.2 Breast Cancer. Gemcitabine for Injection in combination with paclitaxel is indicated for the first-line treatment of patients with metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated.. 1.3 Non-Small Cell Lung Cancer. Gemcitabine for Injection in combination with cisplatin is indicated for the first-line treatment of patients with inoperable, locally advanced (Stage IIIA or IIIB) or metastatic (Stage IV) non-small cell lung cancer (NSCLC).. 1.4 Pancreatic Cancer. Gemcitabine for Injection is indicated as first-line treatment for patients with locally advanced (nonresectable Stage II or Stage III) or metastatic (Stage IV) adenocarcinoma of the pancreas. Gemcitabine for Injection is indicated for patients previously treated with fluorouracil.

INFORMATION FOR PATIENTS SECTION.

17 PATIENT COUNSELING INFORMATION. MyelosuppressionAdvise patients of the risks of myelosuppression Instruct patients to immediately contact their healthcare provider should any signs or symptoms of infection, including fever, or if bleeding or signs of anemia, occur [see Warnings and Precautions (5.2)]. Pulmonary ToxicityAdvise patients of the risks of pulmonary toxicity, including respiratory failure and death. Instruct patients to immediately contact their healthcare provider for development of shortness of breath, wheezing, or cough [see Warnings and Precautions (5.3)]. Hemolytic-Uremic Syndrome and Renal FailureAdvise patients of the risks of hemolytic-uremic syndrome and associated renal failure. Instruct patients to immediately contact their healthcare provider for changes in the color or volume of urine output or for increased bruising or bleeding [see Warnings and Precautions (5.4)]. Hepatic ToxicityAdvise patients of the risks of hepatic toxicity including liver failure and death. Instruct patients to immediately contact their healthcare provider for signs of jaundice or for pain/tenderness in the right upper abdominal quadrant [see Warnings and Precautions (5.5)]. Embryo-Fetal ToxicityAdvise females and males of reproductive potential that Gemcitabine for Injection can cause fetal harm. Advise females of reproductive potential to use effective contraception during treatment with Gemcitabine for Injection and for months after the final dose. Advise male patients with female partners of reproductive potential to use effective contraception during treatment with Gemcitabine for Injection and for months after the final dose [see Warnings and Precaution (5.6), Use in Specific Populations 8.1, 8.3)]. LactationAdvise women not to breastfeed during treatment with Gemcitabine for Injection and for at least one week after the last dose [see Use in Specific Populations (8.2)]. InfertilityAdvise males of reproductive potential of the potential for reduced fertility with Gemcitabine for Injection [see Use in Specific Populations (8.3), Nonclinical Toxicology (13.1)]. Manufactured For: Accord Healthcare, Inc., 1009, Slater Road, Suite 210-B, Durham, NC 27703, USA. Manufactured By: Intas Pharmaceuticals Limited, Ahmedabad 380 054, INDIA. 10 0147 678621/Jul 2019.

NONCLINICAL TOXICOLOGY SECTION.

13 NONCLINICAL TOXICOLOGY. 13.1Carcinogenesis, Mutagenesis, Impairment of Fertility. Long-term animal studies to evaluate the carcinogenic potential of gemcitabine have not been conducted. Gemcitabine was mutagenic in an in vitro mouse lymphoma (L5178Y) assay and was clastogenic in an in vivo mouse micronucleus assay. Gemcitabine intraperitoneal doses of 0.5 mg/kg/day [about 1/700 the 1000 mg/m clinical dose based on body surface area (BSA)] in male mice resulted in moderate to severe hypospermatogenesis, decreased fertility, and decreased implantations. In female mice, fertility was not affected but maternal toxicities were observed at 1.5 mg/kg/day administered intravenously (about 1/200 the 1000 mg/m clinical dose based on BSA) and fetotoxicity or embryolethality was observed at 0.25 mg/kg/day administered intravenously (about 1/1300 the 1000 mg/m2 clinical dose based on BSA).

NURSING MOTHERS SECTION.

8.3 Females and Males of Reproductive Potential. Pregnancy Testing Verify pregnancy status in females of reproductive potential prior to initiating Gemcitabine for Injection [see Use in Specific Populations 8.1)]. Contraception Gemcitabine for Injection can cause fetal harm when administered to pregnant woman [see Use in Specific Populations 8.1)]. Females Because of the potential for genotoxicity, advise females of reproductive potential to use effective contraception during treatment with Gemcitabine for Injection and for months after the final dose of Gemcitabine for Injection. Males Because of the potential for genotoxicity, advise males with female partners of reproductive potential to use effective contraception during treatment with Gemcitabine for Injection and for months after the final dose [see Nonclinical Toxicology 13.1)]. Infertility MalesBased on animal studies, Gemcitabine for Injection may impair fertility in males of reproductive potential [see Nonclinical Toxicology 13.1)]. It is not known whether these effects on fertility are reversible.

OVERDOSAGE SECTION.

10 OVERDOSAGE. There is no known antidote for overdoses of gemcitabine. Myelosuppression, paresthesias, and severe rash were the principal toxicities seen when single dose as high as 5700 mg/m was administered by intravenous infusion over 30 minutes every weeks to several patients in dose-escalation study. In the event of suspected overdose, monitor with appropriate blood counts and provide supportive therapy, as necessary.

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL.

PRINCIPAL DISPLAY PANELNDC 16729- 092-03 Gemcitabine For Injection USP200 mg/vialRx OnlyFor intravenous use only Sterile Single Dose Vial Cytotoxin Agent Lyophilized Must be diluted NDC 16729- 092-03 Gemcitabine For Injection USP200 mg/vial Rx OnlyFor intravenous use onlySterile Single Dose Vial Cytotoxin Agent Lyophilized Must be diluted NDC 16729- 092-03 Gemcitabine For Injection USP200 mg/vial Rx OnlyFor intravenous use onlySterile Single Dose Vial Cytotoxin Agent Lyophilized Must be diluted NDC 16729- 092-03 Gemcitabine For Injection USP200 mg/vial Rx OnlyFor intravenous use onlySterile Single Dose Vial Cytotoxin Agent Lyophilized Must be diluted NDC 16729- 117-11 Gemcitabine For Injection USP1 g/vialRx OnlyFor intravenous use only Sterile Single Dose Vial Cytotoxin Agent Lyophilized Must be diluted NDC 16729- 117-11 Gemcitabine For Injection USP1 g/vialRx OnlyFor intravenous use onlySterile Single Dose Vial Cytotoxin Agent Lyophilized Must be diluted NDC 16729- 117-11 Gemcitabine For Injection USP1 g/vialRx OnlyFor intravenous use only Sterile Single Dose Vial Cytotoxin Agent Lyophilized Must be diluted NDC 16729- 117-11 Gemcitabine For Injection USP1 g/vialRx OnlyFor intravenous use onlySterile Single Dose Vial Cytotoxin Agent Lyophilized Must be diluted NDC 16729- 118-38 Gemcitabine For Injection USP2 g/vialRx OnlyFor intravenous use only Sterile Single Dose Vial Cytotoxin Agent Lyophilized Must be diluted NDC 16729- 118-38 Gemcitabine For Injection USP2 g/vial Rx OnlyFor intravenous use onlySterile Single Dose Vial Cytotoxin Agent Lyophilized Must be diluted NDC 16729- 118-38 Gemcitabine For Injection USP2 g/vialRx OnlyFor intravenous use only Sterile Single Dose Vial Cytotoxin Agent Lyophilized Must be diluted NDC 16729- 118-38 Gemcitabine For Injection USP2 g/vialRx OnlyFor intravenous use only Sterile Single Dose Vial Cytotoxin Agent Lyophilized Must be diluted Gemcitabine For Injection 200mg Carton. Gemcitabine For Injection 200 mg Label. Gemcitabine For Injection 200mg Carton for SEZ. Gemcitabine For Injection 200 mg Label for SEZ. Gemcitabine For Injection 1g Carton. Gemcitabine For Injection g Label. Gemcitabine For Injection 1g Carton for SEZ. Gemcitabine For Injection g Label for SEZ. Gemcitabine For Injection 2g Carton. Gemcitabine For Injection g Label. Gemcitabine For Injection 2g Carton for SEZ. Gemcitabine For Injection g Label for SEZ.

PEDIATRIC USE SECTION.

8.4 Pediatric Use. The safety and effectiveness of gemcitabine have not been established in pediatric patients. The safety and pharmacokinetics of gemcitabine were evaluated in trial in pediatric patients with refractory leukemia. The maximum tolerated dose was 10 mg/m 2/min for 360 minutes weekly for three weeks followed by one-week rest period. The safety and activity of gemcitabine were evaluated in trial of pediatric patients with relapsed acute lymphoblastic leukemia (22 patients) and acute myelogenous leukemia (10 patients) at dose of 10 mg/m 2/min administered over 360 minutes weekly for three weeks followed by one-week rest period. Patients with M1 or M2 bone marrow on Day 28 who did not experience unacceptable toxicity were eligible to receive maximum of one additional four-week course. Toxicities observed included myelosuppression, febrile neutropenia, increased serum transaminases, nausea, and rash/desquamation. No meaningful clinical activity was observed in this trial.

PHARMACOKINETICS SECTION.

12.3 Pharmacokinetics. The pharmacokinetics of gemcitabine were examined in 353 patients, with various solid tumors. Pharmacokinetic parameters were derived using data from patients treated for varying durations of therapy given weekly with periodic rest weeks and using both short infusions (<70 minutes) and long infusions (70 to 285 minutes). The total gemcitabine dose varied from 500 mg/m to 3600 mg/m 2. Distribution The volume of distribution was increased with infusion length. Volume of distribution of gemcitabine was 50 L/m following infusions lasting 70 minutes. For long infusions, the volume of distribution rose to 370 L/m 2. Gemcitabine pharmacokinetics are linear and are described by 2-compartment model. Population pharmacokinetic analyses of combined single and multiple dose studies showed that the volume of distribution of gemcitabine was significantly influenced by duration of infusion and sex. Gemcitabine plasma protein binding is negligible.

RECENT MAJOR CHANGES SECTION.

Warnings and Precautions,Hemolytic Uremic Syndrome 5.4) 5/2019.

REFERENCES SECTION.

15 REFERENCES. 1.OSHA Hazardous Drugs. OSHA. http://www.osha.gov/SLTC/hazardousdrugs/index.html.

SPL UNCLASSIFIED SECTION.

1.1 Ovarian Cancer. Gemcitabine for Injection in combination with carboplatin is indicated for the treatment of patients with advanced ovarian cancer that has relapsed at least months after completion of platinum-based therapy.

USE IN SPECIFIC POPULATIONS SECTION.

8 USE IN SPECIFIC POPULATIONS. Lactation: Advise not to breastfeed. 8.2) 8.1 Pregnancy. Risk Summary Based on animal data and its mechanism of action, gemcitabine can cause fetal harm when administered to pregnant woman [see Clinical Pharmacology (12.1)]. There are no available data on the use of Gemcitabine for Injection in pregnant women. In animal reproduction studies, gemcitabine was teratogenic, embryotoxic, and fetotoxic in mice and rabbits (see Data). Advise pregnant women of the potential risk to fetus [see Use in Special Populations (8.3)]. In the U.S. general population, the estimated background risk of major birth defects and miscarriages in clinically recognized pregnancies is 2-4% and 15-20% respectively.DataAnimal Data Gemcitabine is embryotoxic in mice. Daily dosing of gemcitabine to pregnant mice increased the incidence of fetal malformation (cleft palate, incomplete ossification) at doses of 1.5 mg/kg/day [approximately 0.005 times the 1000 mg/m clinical dose based on body surface area (BSA)]. Gemcitabine was embryotoxic and fetotoxic in rabbits. Daily dosing of gemcitabine to pregnant rabbits resulted in fetotoxicity (decreased fetal viability, reduced litter sizes, and developmental delays) and increased the incidence of fetal malformations (fused pulmonary artery, absence of gall bladder) at doses of 0.1 mg/kg/day (approximately 0.002 times the 1000 mg/m clinical dose based on BSA). 8.2 Lactation. Risk Summary There is no information regarding the presence of gemcitabine or its metabolites in human milk, or their effects on the breastfed infant or on milk production. Due to the potential for serious adverse reactions in breastfed infants from Gemcitabine for Injection, advise women not to breastfeed during treatment with Gemcitabine for Injection and for at least one week following the last dose. 8.3 Females and Males of Reproductive Potential. Pregnancy Testing Verify pregnancy status in females of reproductive potential prior to initiating Gemcitabine for Injection [see Use in Specific Populations 8.1)]. Contraception Gemcitabine for Injection can cause fetal harm when administered to pregnant woman [see Use in Specific Populations 8.1)]. Females Because of the potential for genotoxicity, advise females of reproductive potential to use effective contraception during treatment with Gemcitabine for Injection and for months after the final dose of Gemcitabine for Injection. Males Because of the potential for genotoxicity, advise males with female partners of reproductive potential to use effective contraception during treatment with Gemcitabine for Injection and for months after the final dose [see Nonclinical Toxicology 13.1)]. Infertility MalesBased on animal studies, Gemcitabine for Injection may impair fertility in males of reproductive potential [see Nonclinical Toxicology 13.1)]. It is not known whether these effects on fertility are reversible. 8.4 Pediatric Use. The safety and effectiveness of gemcitabine have not been established in pediatric patients. The safety and pharmacokinetics of gemcitabine were evaluated in trial in pediatric patients with refractory leukemia. The maximum tolerated dose was 10 mg/m 2/min for 360 minutes weekly for three weeks followed by one-week rest period. The safety and activity of gemcitabine were evaluated in trial of pediatric patients with relapsed acute lymphoblastic leukemia (22 patients) and acute myelogenous leukemia (10 patients) at dose of 10 mg/m 2/min administered over 360 minutes weekly for three weeks followed by one-week rest period. Patients with M1 or M2 bone marrow on Day 28 who did not experience unacceptable toxicity were eligible to receive maximum of one additional four-week course. Toxicities observed included myelosuppression, febrile neutropenia, increased serum transaminases, nausea, and rash/desquamation. No meaningful clinical activity was observed in this trial. 8.5 Geriatric Use. In clinical studies which enrolled 979 patients with various malignancies who received single agent gemcitabine, no overall differences in safety were observed between patients aged 65 and older and younger patients, with the exception of higher rate of Grade 3-4 thrombocytopenia in older patients as compared to younger patients. In randomized trial in women with ovarian cancer (Study 1), 175 women received gemcitabine with carboplatin, of which 29% were age 65 years or older. Similar effectiveness was observed between older and younger women. There was significantly higher Grade 3-4 neutropenia in women 65 years of age or older [see Dosage and Administration 2.1) ]. Gemcitabine clearance is affected by age; however, there are no recommended dose adjustments based on patients age [see Clinical Pharmacology 12.3)]. 8.6 Gender. Gemcitabine clearance is decreased in females [see Clinical Pharmacology 12.3)] In single agent studies of gemcitabine, women, especially older women, were more likely not to proceed to subsequent cycle and to experience Grade 3-4 neutropenia and thrombocytopenia [see Dosage and Administration 2.1, 2.2, 2.3, 2.4) ].

WARNINGS AND PRECAUTIONS SECTION.

5 WARNINGS AND PRECAUTIONS. Schedule-Dependent Toxicity: Increased toxicity with infusion time greater than 60 minutes or dosing more frequently than once weekly. 5.1) Myelosuppression: Monitor for myelosuppression prior to each cycle and reduce or withhold dose for severe myelosuppression.( 5.2, 5.7) Pulmonary Toxicity and Respiratory Failure: Discontinue Gemcitabine for Injection for unexplained dyspnea or other evidence of severe pulmonary toxicity. 5.3) Hemolytic-Uremic Syndrome (HUS): Monitor renal function prior to initiation and during treatment. Discontinue Gemcitabine for Injection for HUS or severe renal impairment. 5.4) Hepatic Toxicity: Monitor hepatic function prior to initiation and during treatment. Discontinue Gemcitabine for Injection for severe hepatic toxicity. 5.5) Embryo-Fetal Toxicity: Can cause fetal harm. Advise females and males of reproductive potential to use effective contraception.( 5.6, 8.1) Exacerbation of Radiation Therapy Toxicity: May cause severe and life-threatening toxicity when administered during or within days of radiation therapy. 5.7) Capillary Leak Syndrome: Discontinue Gemcitabine for Injection. 5.8) Posterior Reversible Encephalopathy Syndrome (PRES): Discontinue Gemcitabine for Injection. 5.9) Schedule-Dependent Toxicity: Increased toxicity with infusion time greater than 60 minutes or dosing more frequently than once weekly. 5.1) Myelosuppression: Monitor for myelosuppression prior to each cycle and reduce or withhold dose for severe myelosuppression.( 5.2, 5.7) Pulmonary Toxicity and Respiratory Failure: Discontinue Gemcitabine for Injection for unexplained dyspnea or other evidence of severe pulmonary toxicity. 5.3) Hemolytic-Uremic Syndrome (HUS): Monitor renal function prior to initiation and during treatment. Discontinue Gemcitabine for Injection for HUS or severe renal impairment. 5.4) Hepatic Toxicity: Monitor hepatic function prior to initiation and during treatment. Discontinue Gemcitabine for Injection for severe hepatic toxicity. 5.5) Embryo-Fetal Toxicity: Can cause fetal harm. Advise females and males of reproductive potential to use effective contraception.( 5.6, 8.1) Exacerbation of Radiation Therapy Toxicity: May cause severe and life-threatening toxicity when administered during or within days of radiation therapy. 5.7) Capillary Leak Syndrome: Discontinue Gemcitabine for Injection. 5.8) Posterior Reversible Encephalopathy Syndrome (PRES): Discontinue Gemcitabine for Injection. 5.9) 5.1 Schedule-Dependent Toxicity In clinical trials evaluating the maximum tolerated dose of gemcitabine, prolongation of the infusion time beyond 60 minutes or more frequent than weekly dosing resulted in an increased incidence of clinically significant hypotension, severe flu-like symptoms, myelosuppression, and asthenia. The half-life of gemcitabine is influenced by the length of the infusion [see Clinical Pharmacology (12.3)]. Refer to the recommended Gemcitabine for Injection dosage [see Dosage and Administration (2.1, 2.2, 2.3, 2.4)]. 5.2 Myelosuppression Myelosuppression manifested by neutropenia, thrombocytopenia, and anemia occurs with gemcitabine as single agent and the risks are increased when gemcitabine is combined with other cytotoxic drugs. In clinical trials, Grade 3-4 neutropenia, anemia, and thrombocytopenia occurred in 25%, 8%, and 5%, respectively of the 979 patients who received single agent gemcitabine. The frequencies of Grade 3-4 neutropenia, anemia, and thrombocytopenia varied from 48% to 71%, 8% to 28%, and 5% to 55%, respectively, in patients receiving gemcitabine in combination with another drug [see Adverse Reactions (6.1)]. Prior to each dose of gemcitabine, obtain complete blood count (CBC), with differential and platelet count. Modify the dosage as recommended [see Dosage and Administration (2.1, 2.2, 2.3, 2.4)]. 5.3 Pulmonary Toxicity and Respiratory Failure. Pulmonary toxicity, including interstitial pneumonitis, pulmonary fibrosis, pulmonary edema, and adult respiratory distress syndrome (ARDS), has been reported. In some cases, these pulmonary events can lead to fatal respiratory failure despite the discontinuation of therapy. The onset of pulmonary symptoms may occur up to weeks after the last dose of gemcitabine [see Adverse Reactions 6.1, 6.2)]. Permanently discontinue gemcitabine in patients who develop unexplained dyspnea, with or without bronchospasm, or evidence of severe pulmonary toxicity.. 5.4 Hemolytic Uremic Syndrome Hemolytic uremic syndrome (HUS), including fatalities from renal failure or the requirement for dialysis, can occur with gemcitabine. In clinical trials, HUS occurred in 0.25% of 2429 patients. Most fatal cases of renal failure were due to HUS [see Adverse Reactions 6.1)]. Serious cases of thrombotic microangiopathy other than HUS have been reported with gemcitabine [see Adverse Reactions 6.2)]. Assess renal function prior to initiation of Gemcitabine for Injection and periodically during treatment. Consider the diagnosis of HUS in patients who develop anemia with evidence of microangiopathic hemolysis; increased bilirubin or LDH; reticulocytosis; severe thrombocytopenia; or renal failure (increased serum creatinine or BUN). Permanently discontinue Gemcitabine for Injection in patients with HUS or severe renal impairment. Renal failure may not be reversible even with the discontinuation of therapy.Assess renal function prior to initiation of Gemcitabine for Injection and periodically during treatment. Consider the diagnosis of HUS in patients who develop anemia with evidence of microangiopathic hemolysis; increased bilirubin or LDH; reticulocytosis; severe thrombocytopenia; or renal failure (increased serum creatinine or BUN). Permanently discontinue Gemcitabine for Injection in patients with HUS or severe renal impairment. Renal failure may not be reversible even with the discontinuation of therapy.. 5.5 Hepatic Toxicity Drug-induced liver injury, including liver failure and death, has been reported in patients receiving gemcitabine alone or with other potentially hepatotoxic drugs [see Adverse Reactions 6.1, 6.2)]. Administration of gemcitabine in patients with concurrent liver metastases or pre-existing medical history of hepatitis, alcoholism, or liver cirrhosis can lead to exacerbation of the underlying hepatic insufficiency. Assess hepatic function prior to initiation of gemcitabine and periodically during treatment. Permanently discontinue gemcitabine in patients who develop severe hepatic toxicity. 5.6 Embryo-Fetal Toxicity. Based on animal data and its mechanism of action, gemcitabine can cause fetal harm when administered to pregnant woman. Gemcitabine was teratogenic, embryotoxic, and fetotoxic in mice and rabbits.Advise pregnant women of the potential risk to fetus. Advise females of reproductive potential to use effective contraception during treatment with gemcitabine and for months after the final dose. Advise male patients with female partners of reproductive potential to use effective contraception during treatment with gemcitabine and for months following the final dose [see Use in Specific Populations 8.1, 8.3)]. 5.7 Exacerbation of Radiation Therapy Toxicity Gemcitabine is not recommended for use in combination with radiation therapy.Concurrent (given together or <=7 days apart) Life-threatening mucositis, especially esophagitis and pneumonitis occurred in trial in which gemcitabine was administered at dose of 1000 mg/m to patients with non-small cell lung cancer for up to consecutive weeks concurrently with thoracic radiation. Non-concurrent (given >7 days apart)Excessive toxicity has not been observed when gemcitabine is administered more than days before or after radiation. Radiation recall has been reported in patients who received gemcitabine after prior radiation. 5.8 Capillary Leak Syndrome. Capillary leak syndrome (CLS) with severe consequences has been reported in patients receiving gemcitabine as single agent or in combination with other chemotherapeutic agents [see Adverse Reactions (6.2)]. Permanently discontinue gemcitabine if CLS develops during therapy. 5.9 Posterior Reversible Encephalopathy Syndrome Posterior reversible encephalopathy syndrome (PRES) has been reported in patients receiving gemcitabine as single agent or in combination with other chemotherapeutic agents. [see Adverse Reactions (6.2)]. PRES can present with headache, seizure, lethargy, hypertension, confusion, blindness, and other visual and neurologic disturbances. Confirm the diagnosis of PRES with magnetic resonance imaging (MRI). Permanently discontinue gemcitabine if PRES develops during therapy.